A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy

Shunsuke Kagawa, Shoichiro Ohtani, Noriaki Tanaka, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The phase I study of the tumor suppressor p53 gene therapy for advanced lung cancer was performed. A 57-year-old man with locally advanced squamous cell carcinoma at the tracheal bifurcation, clinical stage IIIB, had previously been treated by radiotherapy and chemotherapy. Because of the local recurrence, he was enrolled to the study. He was treated by a local injection of ADVEXIN once every 4 weeks for 14 times without marked adverse events, which resulted in tumor regression and relief of his symptom for a year. In conclusion, gene therapy with ADVEXIN may be an effective treatment for locally advanced non-small lung cancer.

Original languageEnglish
Pages (from-to)1788-1790
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number11
Publication statusPublished - Oct 2004

Fingerprint

p53 Genes
Tumor Suppressor Genes
Genetic Therapy
Lung Neoplasms
Squamous Cell Carcinoma
Radiotherapy
Recurrence
Drug Therapy
Injections
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy. / Kagawa, Shunsuke; Ohtani, Shoichiro; Tanaka, Noriaki; Fujiwara, Toshiyoshi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 11, 10.2004, p. 1788-1790.

Research output: Contribution to journalArticle

@article{8bbda9ee7abc4c9db6268d91405e61b5,
title = "A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy",
abstract = "The phase I study of the tumor suppressor p53 gene therapy for advanced lung cancer was performed. A 57-year-old man with locally advanced squamous cell carcinoma at the tracheal bifurcation, clinical stage IIIB, had previously been treated by radiotherapy and chemotherapy. Because of the local recurrence, he was enrolled to the study. He was treated by a local injection of ADVEXIN once every 4 weeks for 14 times without marked adverse events, which resulted in tumor regression and relief of his symptom for a year. In conclusion, gene therapy with ADVEXIN may be an effective treatment for locally advanced non-small lung cancer.",
author = "Shunsuke Kagawa and Shoichiro Ohtani and Noriaki Tanaka and Toshiyoshi Fujiwara",
year = "2004",
month = "10",
language = "English",
volume = "31",
pages = "1788--1790",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy

AU - Kagawa, Shunsuke

AU - Ohtani, Shoichiro

AU - Tanaka, Noriaki

AU - Fujiwara, Toshiyoshi

PY - 2004/10

Y1 - 2004/10

N2 - The phase I study of the tumor suppressor p53 gene therapy for advanced lung cancer was performed. A 57-year-old man with locally advanced squamous cell carcinoma at the tracheal bifurcation, clinical stage IIIB, had previously been treated by radiotherapy and chemotherapy. Because of the local recurrence, he was enrolled to the study. He was treated by a local injection of ADVEXIN once every 4 weeks for 14 times without marked adverse events, which resulted in tumor regression and relief of his symptom for a year. In conclusion, gene therapy with ADVEXIN may be an effective treatment for locally advanced non-small lung cancer.

AB - The phase I study of the tumor suppressor p53 gene therapy for advanced lung cancer was performed. A 57-year-old man with locally advanced squamous cell carcinoma at the tracheal bifurcation, clinical stage IIIB, had previously been treated by radiotherapy and chemotherapy. Because of the local recurrence, he was enrolled to the study. He was treated by a local injection of ADVEXIN once every 4 weeks for 14 times without marked adverse events, which resulted in tumor regression and relief of his symptom for a year. In conclusion, gene therapy with ADVEXIN may be an effective treatment for locally advanced non-small lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=16544387248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544387248&partnerID=8YFLogxK

M3 - Article

C2 - 15553716

AN - SCOPUS:16544387248

VL - 31

SP - 1788

EP - 1790

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -